Inflammatory Diseases

  • TP10 – Transplantation: Celldex is developing soluble Complement Receptor Type 1 (sCR1, TP10), a specific and potent inhibitor of complement activation, for use in renal transplantation. TP10 has been previously in clinical trials and demonstrated a good safety profile and complement inhibition. TP10 inhibits the classical, alternative and lectin pathways of complement at both early (C3 convertase) and late (C5 convertase) stages by down-regulating the activation of these cascades. TP10 affects only activated complement, and is not consumed but can recycle in the inhibitory process. Because antigen-antibody complexes directly activate the classical pathway of complement causing local cytotoxicity and inflammation, complement inhibition with TP10 is expected to ameliorate antibody-mediated graft rejection (AMR). Published preclinical studies of TP10 in models of sensitized allograft rejection and of hyperacute xenograft rejection strongly support its use in AMR.

For citations related to TP10 and transplantation click here

Print Page